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Abstract
Scarring is the inevitable outcome of wound healing.This review looks at some of the underlying mechanisms of this complex process with the aim of identifying targets for therapeutic manipulation that could result in reduced scarring or even
scarless wound repair. Fetal wounds are shown to heal without scars primarily due to low levels of TGF-β1 and TGF-β2
and high levels of TGF-β3 as compared to adult wounds which heal with scars. Abnormal excessive scarring in keloid and
hypertrophic scars are also attributed to TGF-β. Clinical manipulation of TGF-β ratios showed promise as a therapeutic
means of controlling scar formation. The effect of the COX enzyme and PGE2 levels remains controversial and more
research is needed to understand the exact roles these molecules play in the wound healing process before they can be
exploited in a clinical setting.
Introduction
Scarring, both as a component and complication of, wound healing affects millions of US citizens every year at a cost of more
than 7 billion dollars (Wilgus, et al. 2003). In addition to esthetic
concerns, scar formation is also implicated clinically in fibrotic
diseases that some reports suggest are responsible for up to 45%
of deaths in the industrial world (Wynn, 2008). Despite such a
heavy toll on the healthcare system, current treatment options
are limited. Further research is needed to understand the underlying causes and mechanisms of scar formation so that effective
treatments and even methods of prevention can be developed.
Cellular response to tissue damage and the consequent formation of fibrotic tissue is a complex process that is still not very
well understood. Current paradigms include the contribution of
such varied cells as epithelial cells, macrophages, T-cells and, of
course, fibroblasts. Initial response to tissue wounds involves the
rapid recruitment of clotting factors and immune inflammatory
moderators to stem blood loss and reduce potential infection
by pathogenic microbes. Later, the relatively extended process of
wound healing begins. Injured epithelial cells undergo a process
of reprogramming, initiation, and propagation of mesenchymal
pathways that includes the ubiquitous TGF-β related pathways.
Macrophages also contribute to the inflammatory response and
secrete profibrotic cytokines as well as growth factors, including
TGF-β, that recruit and activate fibroblasts. Fibroblasts accumulate and ultimately produce and deposit new extracellular matrix
and collagen that replaces normal tissue architecture. It is this
deposition that characterizes scar formation and clinical fibrosis.
Interestingly, the development of scar tissue differs greatly between adult and embryonic wounds. Contrary to the normal
fibrotic result in adult wounds, fetal wounds have been shown to
exhibit scarless healing. Many cellular and molecular differences,
including differences in key inflammatory mediators and various
cytokines and growth factors, have been studied and documented
to attempt to explain this phenomenon.
In addition to expected scarring as a result of injury, there exist
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two clinical examples of atypical wound healing that result in abnormal scar formation. The etiology of hypertrophic scars and
keloids is not well-understood, and although important differences between them have been detailed, both clearly involve the
deposition of excessive amounts of collagen even as compared
to normal scarring.
Such anomalous results, from the scarless healing of fetal wounds
to the excessive scarring of keloid and hypertrophic scars, may
serve as paradigms for understanding the mechanisms behind the
wound healing and scarring processes and the ability to prevent
undesired outcomes.

Methods
Literature searches were chiefly performed using the PubMed
database. After relevant literature was found, related articles
were accessed using the Related Citations feature on the PubMed
website. Additionally, references in these articles were retrieved
and then served as additional points of reference for further research. Review articles relevant to the research topic were helpful in providing references to source material. The Touro College
Online Library and Google Scholar proved to be valuable for
finding and accessing the necessary relevant articles. Moreover,
conversation with plastic surgeons led to additional searches for
source material on the website of the Plastic and Reconstructive
Surgery journal.

Discussion
The formation of scar tissue in the process of wound healing is
both a positive construct that effectively patches breaks in damaged tissue and a negative consequence that can have dire effects.
Scar tissue production is intended to increase the tensile the
strength of wounds but never surpasses 70% of the strength of
the original undamaged tissue (Wilgus, et al. 2003). Scar tissue
also can impede tissue function, restricting mobility in joints and
impairing normal growth in the case of external injuries involving
the skin. The issue is even more problematic in the case of scar
deposition as a result of internal organ damage. In such cases,
scars can dramatically reduce function of vital organs as with
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victims of myocardial infarctions whereby normal heart tissue is
replaced with nonfunctional scar tissue. However, the problem
of scar formation is perhaps greatest with respect to its role in
devastating fibrotic diseases where scar tissue often times fatally
overtakes normal tissue function.
Scars are essentially large deposits of extracellular matrix and
collagen that are deposited by activated fibroblasts in response
to tissue damage. After an injury, inflammatory mediators are
immediately recruited and activated. Numerous cell types are
involved in this response which includes the production and
excretion of various growth factors and cytokines such as the
well-studied TGF-β, IL-6, IL-8 and others.
Tissue injury involves disruption of capillaries and immediately triggers activation of platelets which begin a clotting cascade. Inflammatory events follow with recruitment of neutrophils which secrete a variety of growth factors and cytokines.
Monocytes arrive to facilitate changes in the wound matrix and
macrophages release factors that activate fibroblasts to begin
adding hyaluronate and glycoproteins such as fibronectin to the
extracellular matrix (ECM). Gradually, these fibroblasts shift to
producing proteoglycans and collagen which are then deposited
at the wound site. Over the course of several days, macrophages
and fibroblasts work to remodel the matrix and thus convert the
granulation tissue into scar tissue (Harty, 2003).
Studies comparing scarless fetal wounds to adult wounds have
found significant differences in the levels of proinflammatory cytokines such as IL-6 and IL-8. Liechty et al. (1998) grafted adult
and fetal skin subcutaneously into SCID mice, wounded the site
and subsequently excised the wound after varying lengths of time.
The presence of IL-8 was confirmed using reverse transcription
polymerase chain reaction (RT-PCR). Their results showed that
fetal fibroblasts produced significantly less IL-8 at baseline (50
+/- 6 pg/mL versus 450 +/- 115 pg/mL, P < 0.001). IL-8 mRNA
was detected in unstimulated adult fibroblasts but not in fetal
fibroblasts and much less IL-8 mRNA was detected in stimulated
fetal fibroblasts than in adult fibroblasts. IL-8 mRNA was detected 4 hours after wounding in both fetal and adult wounds but by
12 hours no IL-8 mRNA was detected in fetal wounds, whereas
IL-8 mRNA persisted for up to 72 hours in adult wounds.
In a similar experiment, Liechty et al. (2000a) excised incisional
wounds and examined them for IL-6 mRNA quantification by RTPCR. As with IL-8, fetal fibroblasts produced less IL-6 protein and
mRNA at all points examined (P < 0.01 vs adult). IL-6 mRNA was
detected 4 hours after wounding in both fetal and adult wounds.
By 12 hours there was no IL-6 mRNA in the fetal wounds but the
adult wounds had IL-6 mRNA persisting to 72 hours. In this experiment, another set of grafts had 5 micrograms of IL-6 injected

at wounding and the wound subsequently harvested at 7 days for
analysis. The wounds with administered IL-6 resulted in scar formation. Since these cytokines are responsible for the recruitment
and activation of various leukocytes including macrophages, the
diminished inflammatory response by fetal tissues may explain
the lack of cellular recruitment and inflammation in fetal wound
healing and further suggests that the inflammatory response
plays a key role in the process of scar formation.
One well studied growth factor, TGF-β, exists as three known
isoforms and is involved in many aspects of wound healing, from
the immediate inflammatory response to matrix deposition
(Adzick & Lorenz, 1994). In response to tissue injury, macrophages release TGF-β which stimulates the deposition of collagen
and other matrix components by fibroblasts, thus implicating it in
the etiology of fibrosis. Specifically, the TGF-β1 and TGF-β2 isoforms have been directly implicated in the fibrotic response and
formation of scar tissue. Whitby and Ferguson (1991) detected
both TGF-β1 and TGF-β2 isoforms with immunolocalization in
adult wounds but not in fetal wounds. In a pioneer study, Shah et
al. (1992) studied the effect of reduced levels of TGF-β in adult
rodent wounds by using various neutralizing agents. The results
of that experiment indicated inhibited fibrosis and scar formation. In another similar experiment, Shah et al. (1994) injected a
polyclonal neutralizing antibody to TGF-β1, 2 into full-thickness
cutaneous wounds of adult rodents just prior to wounding or
within 24 hours of wounding and repeated daily for two days
post-wounding. The effect was successful reduction in scarring.
Numerous similar studies have been performed that confirm
these results with more or less comparable data (Singer, et al.
2009; Shah, et al. 2000). Conversely, up-regulation of these TGF-β
isoforms via exogenous application resulted in excessive scar
formation in a number of animal models (Lin, et al. 1995; Wang,
et al. 1999; Lanning, et al. 1999). Thus direct evidence exists that
increased levels of TGF-β1 and TGF-β2 play an important role in
the fibrotic response and suggests that manipulation of TGF-β
levels may provide an efficient strategy of reducing scar formation.
The culpability of TGF-β in the formation of scar tissue is further supported by studies that have investigated the cellular and
molecular differences abnormal scar formation such as keloid
and hypertrophic scars. Experimental evidence suggests that
upregulation of TGF-β is necessary for the excessive scarring
characteristic of these pathologies (Lee, et al. 1999; Campaner,
et al. 2006). Wang et al. (2000) compared the levels of TGF-β1
mRNA in hypertrophic scar tissue and normal skin and found
that hypertrophic scar tissues expressed five-fold more TGF-β1
mRNA than normal skin per unit of wet weight. TGF-β1 mRNA
expression in 5 pairs of fibroblast cultures derived from hypertrophic scar tissue also was found to be significantly elevated as
compared to those derived from normal cells (116 +/- 6 vs. 97
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+/- 7, p = 0.017). Additionally, Schmid (1998) demonstrated by
immunohistochemistry and in situ hybridization, that hypertrophic scars exhibit unresolved persistent overexpression of TGF-β
receptors by fibroblasts leading to overproduction of matrix protein and subsequent fibrosis.
Table 1

TGF-β Isoform

Scarless Fetal
Healing

Scar-forming
Adult Healing

TGF-β1

low/absent

high

TGF-β2

low/absent

high

TGF-β3

high

low

Summary of relative TGF-β isoform differences in scarless fetal wound healing
and scar-forming adult wound healing. (Ferguson, O’Kane, 2004).

However, although the TGF-β1 and TGF-β2 isoforms have been

implicated in scar formation, a third isoform has been shown to
reduce scarring. Whitby and Ferguson (1991) demonstrated that
fetal wounds express low levels of TGF-β1 and TGF-β2 but high
levels of the third isoform, TGF-β3 (Table 1).
This implied that the ratio of TGF-β isoforms in wounded tissue
may be the key to understanding the mechanism of wound healing and whether or not a scar forms. Shah et al. (1995) confirmed
this hypothesis when they demonstrated that pan-neutralization
of all three known TGF-β isoforms in linear incisions made on
rats did not improve scarring, while exogenous application of
TGF-β3 resulted in marked improvement in scarring and even
scarless healing. Numerous studies have exploited this therapeutic approach of increasing the relative ratio of TGF-β3 to TGF-β1
and TGF-β2 with novel pharmaceutical agents (Ferguson, O’Kane,
2004) (Figure 1).
The first clinical application of human recombinant TGF-β3,
avotermin (Juvista; Renovo, UK) administered as an intradermal
injection at the time of surgery, had shown promise in reducing scarring in controlled, double-blind, randomized phase I/
II clinical studies (Durani, et al. 2008). So et al. (2011) studied
sixty patients (35 men and 25 women; age, 19 to 78 years; 53
Caucasians; scar length, 5 to 21 cm) who received intradermal

Figure 1
macroscopic: black
dots indicate ends of incision
(a)
normal scar
histological score - 4

scar: dense abnormally
organized dermis
histology

(b)
no visible scar
histological score - 0.5

improved dermal organization
similar to normal skin
histology

(a) Placebo-treated incisional rat wound compared with (b) scarless healing in TGF-β3-treated wound 84 days post-wounding (Ferguson, O’Kane, 2004).
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avotermin (200 ng/100 μl/linear cm wound margin) and placebo
to wounds immediately after scar revision surgery and again 24
hours later. Primary efficacy was measured as a total scar score
derived from a visual analogue scale and scored by a lay panel
from standardized photographs from 1 to 7 months following
treatment. Profilometry showed a greater reduction in scar surface area from baseline with avotermin treatment compared with
placebo and histologic analysis showed collagen organization that
more closely resembled normal skin. However, an earlier study
of dermal ulcers on the ears of female rabbits had demonstrated only that exogenous topical TGF-β3 had accelerated wound
healing but with no improvement in scar morphology and prominence. Wu et al. (1997) showed that the use of TGF-β3 (0.3-0.75
microgram per wound) increased granulation tissue formation
by more than 100% (P < .005) but no significant difference in the
hypertrophic index was noted as compared with controls. In fact,
phase III trials of avotermin failed to meet primary and secondary
endpoints, suggesting that the difference between scarless and
scar-forming wound healing is perhaps more complex than simply
altering the ratio of TGF-β isoforms (Penn, et al. 2012) .
Interestingly, a number of studies have demonstrated that even
in fetal wounds, exogenously applied TGF-β can induce fibrosis.
McCallion and Ferguson (1996) applied exogenous TGF-β1 to
fetal wounds and observed a profound fibrotic response with
scar formation. Krummel et al. (1988) showed that the addition
of TGF-β to polyvinyl alcohol sponges implanted in fetal rabbits
produced fibrosis. Sullivan et al. (1995) also examined human scarless fetal wounds transplanted subcutaneously into adult nude
mice. Immunohistochemistry performed on the wounds did not
show TGF-β staining. In a second part of the study, a slow-release
disk with varying amounts of TGF-β1 was placed beneath the
fetal skin graft at the time of wounding. Marked scarring in these
fetal grafts was observed fourteen days post-wounding with the
size of the scar proportional to the amount of TGF-β1 applied.
These data suggest that the cellular mechanism of scar formation
characteristic of adult wound healing is present in fetal wounds.
The absence of scar formation in fetal wounds thus implies active
suppression of these inflammatory mediators that have been implicated in scar formation.
The concept of immune inflammatory suppression as the mechanism of scarless healing has been investigated further by testing
with the known anti-inflammatory cytokine IL-10. IL-10 deactivates macrophages and inhibits expression of both IL-6 and IL-8.
Liechty et al. (2000b) hypothesized that the diminished levels of
IL-6 and IL-8 they had revealed in a previous study were in fact
due to the effects of IL-10. They developed a new syngeneic murine model of fetal wound repair in which 15-day-gestation skin
from either normal or transgenic IL-10 knockout mice was grafted to the back of the same strain adult mice. Incisions were made

in the grafts after 5 days, which were then harvested at 1 week
and analyzed for inflammatory response and scar formation. The
normal fetal skin grafts showed minimal inflammation and were
histologically consistent with scarless healing.The IL-10 knockout
fetal skin grafts, in contrast, displayed significant inflammation and
scar formation. Thus, the anti-inflammatory effects of IL-10 are
necessary for active suppression of the inflammatory response
leading to the observed paucity of macrophages, less TGF-β release, and consequently, less scarring.
The impact of IL-10-induced immune suppression is a key factor in scarless wound healing. Yamamoto et al. (2001) performed
Northern blot analysis to show that IL-10 differentially regulates
collagen deposition by downregulation of TGF-β1-induced collagen mRNA. In a phase II randomized controlled clinical trial,
Kieran et al. (2013) demonstrated that exogenous IL-10 applied
to human incisional wounds reduced scarring and generally improved scar appearance.
In a recent study, Wise et al. (2014) studied the effects of a purified IL-10 homolog derived from orf virus (ovIL-10). Orf virus
infections induce persistent skin lesions that are reminiscent of
sustained wound healing, yet surprisingly resolve with minimal
scarring (Gurel 2002), and genetic studies have discovered that
orf virus encodes for a variety of factors that allow it to subvert
host immune responses, including an IL-10 homolog (Fleming
2007). Wise et al. made excisional wounds in mice and divided
them into four groups. The first three groups were treated with
either recombinant murine IL-10 (mIL-10) or ovIL-10 in a buffered saline solution (PBS), or PBS alone, while the fourth group
received no treatment. The wounds were biopsied at varying
times and analyzed. Histological analysis revealed that wounds
treated with ovIL-10 exhibited accelerated healing as evident
by increased wound reepithelialization as compared to controls.
Reduction in visible scarring was also evident and quantitative
PCR confirmed decreased levels of key proinflammtory mediators. Thus supporting evidence exists that limiting the inflammatory response in wound healing can improve the quality of
wound repair.
TGF-β is an upstream regulator of the cyclooxygenase (COX)
pathway (Wilgus, et al. 2004). COX enzymes catalyze the conversion of membrane phospholipid-derived arachidonic acid into
prostaglandins which are known mediators of the inflammatory
response. Western blot analysis and immunohistochemistry of
biopsied hypertrophic and keloid scar lesions revealed significant
overexpression of COX-1 and COX-2 isoforms, respectively, in
comparison to normal dermal tissue which further suggests a significant role these enzymes play in the pathogenesis of these abnormal scarring processes (Rossiello, et al. 2009). Indeed, TGF-β
was shown to induce prostaglandin production in cultured
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fibroblasts via COX-1 overexpression (Diaz, et al. 1998).
The significance of COXs in the etiology of pathological scarring
such as keloids and hypertrophic scars has led to the investigation of its role in wound healing in general. Wilgus et al. (2003)
examined the role of COX inhibitors in reducing scar formation.
Celecoxib belongs to the family of nonsteroidal anti-inflammatory drugs (NSAIDs) which target the COX enzymes. Specifically,
celecoxib selectively targets COX-2 and prevents its enzymatic
activity and subsequent production of prostaglandins including
prostaglandin E2 (PGE2). Wilgus et al. made full-thickness incisions in mice and closed the wounds with stainless steel wound
clips to mimic surgical wounds. The staples were removed after
5 days. The wounds were treated topically immediately after
wounding and for up to 14 days daily with either 200 µl of the
vehicle control (K-Y Jelly; Ortho Pharmaceutical Corp., Raritan,
NJ) or with 1 mg of celecoxib capsules (Celebrex®, Searle, St.
Louis, MO) dissolved in 200 µl of vehicle such that 200 µl contained 1 mg of the drug.
Skin sections were excised and analyzed. Immunohistochemical
analysis using an antibody specific for the neutrophil surface
marker Ly-6G, revealed a stark contrast between vehicle-treated
and celcoxib-treated wounds. While a major inflammatory response, manifested as a massive infiltration of neutrophils, was
observed in the vehicle-treated wounds in comparison to unwounded tissue, wounds treated with celecoxib were virtually
devoid of neutrophils.
Additionally, Biotrak enzyme immunoassays (EIA; AmershamPharmacia, Piscataway, NJ) were used to quantify the concentration of PGE2. An approximately 50% decrease in wound PGE2
levels was observed in wounds treated with celecoxib (p < 0.05).
Levels of TGF-β1 were examined by Western blot analysis which
revealed significantly lower levels in celecoxib-treated wounds
compared to vehicle-treated wounds. These data were substantiated by the observation of reduced scarring later on.
Wilgus et al. (2003) also reported that PGE2 promotes fibroblast
proliferation and collagen synthesis consistent with known findings (Lupulescu 1975) as well as their data showing decreased
scar tissue deposition in treatment with celecoxib. This seems to
be corroborated by the fact that lower levels of the proinflammatory fibrogenic TGF-β1 were detected. A similar result was
presented by Miyajima et al. (2001) who also showed the ability
of COX-2 inhibitors to reduce TGF-β levels and thus fibrosis.
The demonstrated effect of treatment with topical celecoxib in
reducing scar formation in adult wound healing led Wilgus et al.
(2004) to examine the role of COX-2 in scarless fetal wound
repair. Incisions were made in the dorsum of fetal mice at either
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15 (E15) or 18 (E18) days after the detection of a vaginal plug
using microsurgical scissors.These time points represent the ages
at which either scarless or fibrotic healing occurs. Normal E15
and E18 skin were harvested as controls along with the wounded
samples at varying times for examination. Immunohistochemical
staining at 24 hours post-wounding demonstrated COX-2 protein expression only in wounded E18 skin but not in E15 skin.
Western blot was also used to detect COX-2 protein and the
levels were analyzed by image analysis software. Levels of COX-2
protein as well as PGE2 were higher in wounds introduced at E18
compared to those at E15, implying that COX-2 is involved in the
process of scar tissue formation.
It is thought that one mechanism by which PGE2 contributes to
scar deposition is by increasing the rate of fibroblast proliferation. Indeed, Wilgus et al. showed that exogenous PGE2 applied
to fetal fibroblast cultures resulted in statistically significant (p
< 0.05 compared to untreated cells) dose dependent increased
proliferation.
However, conflicting data suggest that fibroblasts from other organs do not respond in the same way to increased PGE2 levels.
For example, PGE2 reduces proliferation and collagen synthesis by lung fibroblasts. This suggests that PGE2 can have varied
effects perhaps resulting from differences in the expression or
activity of various PGE2 receptors (Wilgus 2004).
Thus, the mechanism of PGE2-induced scarring could involve a
number of plausible options. PGE2 could be contributing to the
inflammatory response which has already been implicated in scar
formation. Alternatively, PGE2 could be promoting scar deposition through increases in the profibrotic TGF-β. Lastly, PGE2
could be directly encouraging scar formation by stimulating fibroblast proliferation.
Of note, however, is that although keloid and hypertrophic scars
were found to express high levels of COX proteins, Yeh et al.
(2006) found that fibroblasts derived from keloid patients exhibited diminished capacity to produce PGE2, in line with the studies
that identified PGE2 as an antifibrotic agent. In this experiment,
fibroblast cultures were stimulated using the proinflammatory
cytokine IL-1 which is known to activate fibroblasts and induce
the formation/release of COX pathway products such as PGE2
(Elias, et al. 1987). The effects of PGE2 on the synthesis of collagen were determined using enzyme-linked immunosorbant assay
(ELISA) kits. According to these data, the excessive deposition of
collagen characteristic of keloids may in fact be due to decreased
levels of PGE2 rather than increased.
The conflicting and perhaps confounding data surrounding PGE2
and its effect on fibroblast proliferation and collagen synthesis
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necessitate further investigation into the exact mechanisms by
which this enzyme affects the healing process. Such contradictory
data does not now lend to sufficient understanding that can lead
to exploitation and development of therapeutic clinical applications in the treatment or prevention of scarring. In fact, some
have suggested that the use of NSAIDs and COX-2 inhibitors
may even exacerbate wound scarring because of their ability to
decrease PGE2 production (Su, et al. 2010).
Until such time as the role of PGE2 and its effect on wound
healing becomes better understood, a more promising approach
to treatment and/or prevention of scarring would seem to be
manipulation of the various TGF-β isoforms, which perhaps play a
more direct role in the process of scar formation .
Already, clinical trials that manipulated the ratio of TGF-β isoforms have proven efficacy in the controlling scarring, although
not without some failure. Further investigation into the exact
role the various isoforms of TGF-β play in the process of wound
healing can hopefully lead to the development of better targeted
therapies to reduce scarring and perhaps even cure the numerous fibrotic diseases.
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